HER2 and ABCC1 are identified as significant transcriptomic predictors of overall survival in patients treated with T-DXd. A large-scale analysis reveals novel predictors of survival and resistance ...

Parse Biosciences launches a fully integrated immune repertoire and whole transcriptome analysis workflow in its data analysis platform, Trailmaker.

The NCCN guidelines now include MammaPrint for identifying HR+/HER2- early-stage breast cancer patients who may benefit from ...

Since the advent of the Human Genome Project, scientists have expanded efforts to map complete biological datasets that encompass entire molecular families, such as DNA, RNA, proteins, and metabolites ...

Scientists can peer into cells to get a limited view of their activity using microscopes and other tools. However, cells and ...

SEATTLE--(BUSINESS WIRE)--Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced a significant update to the company’s flagship Evercode™ ...

Parse Biosciences introduces workflow for immune repertoire and transcriptome analysis: Seattle Saturday, January 24, 2026, 15:00 Hrs [IST] Parse Biosciences, the leading provider ...